Utilidad de la densidad de la prueba de antígeno prostático especifico como predictor de cáncer de próstata

Abstract

Background: Prostate specific antigen (PSA) is a protein, belonging to the protease enzyme group, and is used as a biomarker for prostate cancer screening. The Gold Standard for prostate biopsy is the PSA test, as it is an examination that approximates a viable diagnosis of prostate cancer with a sensitivity of up to 70% and specificity of 79%. Because of this, quantitative values are directly related to the severity of this oncological pathology. A cut-off point for prostate specific antigen density (PSAD) of 0.15 ng/mL/cc has been established. A value exceeding the cut-off point is considered a clinically significant finding of prostate cancer and indicates a prostate biopsy. Objective: To determine the diagnostic utility of PSA density in prostate cancer. Methodology: Ninety-two articles were reviewed using PubMed, Scopus, and Web of Science databases, searching for the words Biomarker, prostate cancer, PSA density, and specificity. Nine articles were included. Results: The search strategy yielded nine articles demonstrating that PSA density is superior to PSA alone in the diagnosis of prostate cancer.